KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Net Income (2016 - 2025)

Eli Lilly (LLY) has disclosed Net Income for 16 consecutive years, with $6.6 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 50.52% year-over-year to $6.6 billion, compared with a TTM value of $20.6 billion through Dec 2025, up 94.9%, and an annual FY2025 reading of $20.6 billion, up 94.9% over the prior year.
  • Net Income was $6.6 billion for Q4 2025 at Eli Lilly, up from $5.6 billion in the prior quarter.
  • Across five years, Net Income topped out at $6.6 billion in Q4 2025 and bottomed at -$57.4 million in Q3 2023.
  • Average Net Income over 5 years is $2.4 billion, with a median of $1.8 billion recorded in 2022.
  • The sharpest move saw Net Income tumbled 103.95% in 2023, then soared 1790.42% in 2024.
  • Year by year, Net Income stood at $1.7 billion in 2021, then rose by 12.26% to $1.9 billion in 2022, then increased by 12.98% to $2.2 billion in 2023, then skyrocketed by 101.43% to $4.4 billion in 2024, then soared by 50.52% to $6.6 billion in 2025.
  • Business Quant data shows Net Income for LLY at $6.6 billion in Q4 2025, $5.6 billion in Q3 2025, and $5.7 billion in Q2 2025.